Home / Associations between PSA kinetics and cause-specific mortality in patients with localised prostate cancer managed observationally: A sub-group analysis of the SPCG-6 study
Associations between PSA kinetics and cause-specific mortality in patients with localised prostate cancer managed observationally: A sub-group analysis of the SPCG-6 study
Men with non-metastatic prostate cancer randomized to placebo in the SPCG-6 trial had a higher risk of dying of non-PCA related disease (38%) compared to PCA related mortality (31%) at 15 years. Early PSA kinetics after randomization were only useful to predict survival in men with PSA between 10-25ng/ml. The risk of dying of prostate cancer almost doubled when initial PSADT was <3 years (42%) as compared >3 years (25%). Interestingly, in men with higher PSA values at baseline, kinetics had little predictive value for survival.
This website uses cookies to improve user experience. By using our website you consent to all cookies in accordance with our Privacy Policy.
Men with non-metastatic prostate cancer randomized to placebo in the SPCG-6 trial had a higher risk of dying of non-PCA related disease (38%) compared to PCA related mortality (31%) at 15 years. Early PSA kinetics after randomization were only useful to predict survival in men with PSA between 10-25ng/ml. The risk of dying of prostate cancer almost doubled when initial PSADT was <3 years (42%) as compared >3 years (25%). Interestingly, in men with higher PSA values at baseline, kinetics had little predictive value for survival.